Fast-growing evergreen

A larger and earlier than expected payout from Ogeda S.A. could substantially increase the size of Fund+’s evergreen life sciences fund, leading the firm to consider broadening its investment strategy.

On April 3, Astellas Pharma Inc. (Tokyo:4503) announced plans to acquire Ogeda for €500 million ($533.3 million) up front and up to €300 million ($320 million) in milestones. Lead candidate fezolinetant (ESN364), an agonist of neurokinin 3 receptor (TACR3; NK3R), will enter a Phase IIb study in hot flashes mid-year. ...